Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
Recent Articles
Afibrinogenemia: A Rare, Often Overlooked Bleeding Disorder
Afibrinogenemia is a very rare, inherited blood disorder in which the blood does not clot normally because of a mutation that leads to the...
Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies
In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high...
Evaluating Two New Options for Hereditary Hemorrhagic Telangiectasia
At EHA2021 Virtual, researchers shared safety and efficacy findings of two agents for the treatment of the rare disease hereditary hemorrhagic telangiectasia (HHT): pazopanib...
Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma
In the GELTAMO ICML-2015 study, treatment with frontline ibrutinib in combination with rituximab demonstrated high rates of efficacy in patients with indolent mantle cell...
Evaluating a Response-Adapted Rituximab Approach for Patients With Follicular Lymphoma
In patients with follicular lymphoma (FL), standard rituximab maintenance produced better rates of progression-free survival (PFS) than an experimental response-adopted approach, according to results...
Current Issue
July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9
This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.